• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

盐酸齐拉西酮一水合物纳米晶体的Caco-2细胞渗透性研究

Caco-2 Cell Permeability Studies of Ziprasidone Hydrochloride Monohydrate Nanocrystals.

作者信息

Karaküçük Alptuğ, Taşhan Emine, Öztürk Naile, Çelebi Nevin

机构信息

Gazi University Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey

Ankara Medipol University Faculty of Pharmacy, Department of Pharmaceutical Technology, Ankara, Turkey

出版信息

Turk J Pharm Sci. 2021 Apr 20;18(2):223-227. doi: 10.4274/tjps.galenos.2020.67366.

DOI:10.4274/tjps.galenos.2020.67366
PMID:33902264
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8100775/
Abstract

OBJECTIVES

The current study focused on the evaluation of the cytotoxic effect and permeability of ziprasidone hydrochloride monohydrate (ZHM) nanocrystals on Caco-2 cells.

MATERIALS AND METHODS

ZHM nanocrystals were prepared by the microfluidization method in the presence of polyvinylpyrrolidone as a stabilizer. Particle size (PS), particle size distribution (PDI), and zeta potential (ZP) values were measured in characterization studies. cytotoxic effects of ZHM nanocrystals were investigated using the 3-(4,5-dimetylthiazol-2-yl)-2,5-diphenyltetrazolium bromide test. Caco-2 transport studies were conducted with formulations of ZHM coarse powder and nanocrystals.

RESULTS

Nanocrystals were obtained with 400-600 nm PS, 0.1-0.4 PDI, and >20 mV ZP values. The cell viability remained 100% for all sample groups. The permeability value of ZHM nanocrystals through Caco-2 cells increased 2.3-fold in comparison with ZHM coarse powder. Cumulative drug transport also increased at the end of the sampling period.

CONCLUSION

Nanocrystal technology helps to increase the permeability of drug particles by increasing the saturation solubility.

摘要

目的

本研究聚焦于评估盐酸齐拉西酮一水合物(ZHM)纳米晶体对Caco-2细胞的细胞毒性作用及通透性。

材料与方法

在聚乙烯吡咯烷酮作为稳定剂的情况下,通过微流化法制备ZHM纳米晶体。在表征研究中测量粒径(PS)、粒径分布(PDI)和zeta电位(ZP)值。使用3-(4,5-二甲基噻唑-2-基)-2,5-二苯基四氮唑溴盐试验研究ZHM纳米晶体的细胞毒性作用。用ZHM粗粉和纳米晶体的制剂进行Caco-2转运研究。

结果

获得了粒径为400 - 600 nm、粒径分布为0.1 - 0.4且zeta电位值>20 mV的纳米晶体。所有样品组的细胞活力均保持在100%。与ZHM粗粉相比,ZHM纳米晶体通过Caco-2细胞的通透性值增加了2.3倍。在取样期结束时,累积药物转运也增加了。

结论

纳米晶体技术通过提高饱和溶解度有助于增加药物颗粒通透性。

相似文献

1
Caco-2 Cell Permeability Studies of Ziprasidone Hydrochloride Monohydrate Nanocrystals.盐酸齐拉西酮一水合物纳米晶体的Caco-2细胞渗透性研究
Turk J Pharm Sci. 2021 Apr 20;18(2):223-227. doi: 10.4274/tjps.galenos.2020.67366.
2
Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.纳米晶齐拉西酮口崩片的研制:通过实验设计和体外评价进行优化。
AAPS PharmSciTech. 2020 Apr 15;21(3):115. doi: 10.1208/s12249-020-01653-9.
3
Development of surface stabilized candesartan cilexetil nanocrystals with enhanced dissolution rate, permeation rate across CaCo-2, and oral bioavailability.表面稳定化坎地沙坦西酯纳米晶的研制,提高了溶解速率、跨 CaCo-2 的渗透速率和口服生物利用度。
Drug Deliv Transl Res. 2016 Oct;6(5):498-510. doi: 10.1007/s13346-016-0297-8.
4
Dissolution enhancement and in vitro performance of clarithromycin nanocrystals produced by precipitation-lyophilization-homogenization method.沉淀-冻干-均质法制备的克拉霉素纳米晶体的溶出度增强及体外性能
Eur J Pharm Biopharm. 2014 Nov;88(3):886-96. doi: 10.1016/j.ejpb.2014.08.013. Epub 2014 Sep 6.
5
Impact of uncharged and charged stabilizers on in vitro drug performances of clarithromycin nanocrystals.无电荷和带电荷稳定剂对克拉霉素纳米晶体体外药物性能的影响。
Eur J Pharm Biopharm. 2019 Apr;137:68-76. doi: 10.1016/j.ejpb.2019.02.004. Epub 2019 Feb 12.
6
Characterization and evaluation in vivo of baicalin-nanocrystals prepared by an ultrasonic-homogenization-fluid bed drying method.超声均质-流化床干燥法制备黄芩苷纳米晶体的体内表征与评价
Chin J Nat Med. 2014 Jan;12(1):71-80. doi: 10.1016/S1875-5364(14)60012-1.
7
Enhancement of cellular uptake, transport and oral absorption of protease inhibitor saquinavir by nanocrystal formulation.纳米晶体制剂增强蛋白酶抑制剂沙奎那韦的细胞摄取、转运及口服吸收
Acta Pharmacol Sin. 2015 Sep;36(9):1151-60. doi: 10.1038/aps.2015.53. Epub 2015 Aug 10.
8
Fabrication and Characterization of Gliclazide Nanocrystals.格列齐特纳米晶体的制备与表征
Adv Pharm Bull. 2018 Aug;8(3):419-427. doi: 10.15171/apb.2018.049. Epub 2018 Aug 29.
9
Preparation, characterization and pharmacokinetic evaluation of rosuvastatin calcium incorporated cyclodextrin-polyanhydride nanoparticles.载罗苏伐他汀钙的环糊精-聚酸酐纳米粒的制备、表征及药代动力学评价。
Drug Dev Ind Pharm. 2019 Oct;45(10):1635-1645. doi: 10.1080/03639045.2019.1648501. Epub 2019 Aug 6.
10
Improved oral bioavailability for lutein by nanocrystal technology: formulation development, in vitro and in vivo evaluation.纳米晶体技术提高叶黄素的口服生物利用度:制剂开发、体外和体内评价。
Artif Cells Nanomed Biotechnol. 2018 Aug;46(5):1018-1024. doi: 10.1080/21691401.2017.1358732. Epub 2017 Jul 27.

引用本文的文献

1
and chemometrics, cell toxicity and permeability of naringenin 8-sulphonate and derivatives.以及柚皮素8-磺酸盐及其衍生物的化学计量学、细胞毒性和渗透性。
Front Pharmacol. 2024 Jul 24;15:1398389. doi: 10.3389/fphar.2024.1398389. eCollection 2024.
2
Caco-2 Cell Line Standardization with Pharmaceutical Requirements and In Vitro Model Suitability for Permeability Assays.符合药品要求的Caco-2细胞系标准化及用于渗透性测定的体外模型适用性
Pharmaceutics. 2023 Oct 24;15(11):2523. doi: 10.3390/pharmaceutics15112523.

本文引用的文献

1
Investigation of Formulation and Process Parameters of Wet Media Milling to Develop Etodolac Nanosuspensions.湿磨法制备依托度酸纳米混悬剂的处方和工艺参数研究。
Pharm Res. 2020 May 31;37(6):111. doi: 10.1007/s11095-020-02815-x.
2
Development of Nanocrystal Ziprasidone Orally Disintegrating Tablets: Optimization by Using Design of Experiment and In Vitro Evaluation.纳米晶齐拉西酮口崩片的研制:通过实验设计和体外评价进行优化。
AAPS PharmSciTech. 2020 Apr 15;21(3):115. doi: 10.1208/s12249-020-01653-9.
3
Development of daidzein nanosuspensions: Preparation, characterization, in vitro evaluation, and pharmacokinetic analysis.大豆黄素纳米混悬剂的研制:制备、表征、体外评价及药代动力学分析。
Int J Pharm. 2019 Jul 20;566:67-76. doi: 10.1016/j.ijpharm.2019.05.051. Epub 2019 May 21.
4
Enhanced dissolution/caco-2 permeability, pharmacokinetic and pharmacodynamic performance of re-dispersible eprosartan mesylate nanopowder.重分散甲磺酸依普罗沙坦纳米粉末的溶出度/ Caco-2 渗透率增强、药代动力学和药效学性能。
Eur J Pharm Sci. 2019 Apr 30;132:72-85. doi: 10.1016/j.ejps.2019.02.021. Epub 2019 Feb 22.
5
Evaluation of improved oral bioavailability of ritonavir nanosuspension.评价利托那韦纳米混悬液的口服生物利用度改善情况。
Eur J Pharm Sci. 2019 Apr 1;131:153-158. doi: 10.1016/j.ejps.2019.02.028. Epub 2019 Feb 18.
6
Preparation of ritonavir nanosuspensions by microfluidization using polymeric stabilizers: I. A Design of Experiment approach.使用聚合物稳定剂通过微流化法制备利托那韦纳米混悬液:I. 实验设计方法
Eur J Pharm Sci. 2016 Dec 1;95:111-121. doi: 10.1016/j.ejps.2016.05.010. Epub 2016 May 13.
7
The improvement of the dissolution rate of ziprasidone free base from solid oral formulations.提高齐拉西酮游离碱从固体口服制剂中的溶出速率。
AAPS PharmSciTech. 2015 Aug;16(4):922-33. doi: 10.1208/s12249-015-0285-1. Epub 2015 Jan 16.
8
Nanocrystals of medium soluble actives--novel concept for improved dermal delivery and production strategy.中溶性活性物质的纳米晶体--改善经皮给药的新概念和生产策略。
Int J Pharm. 2014 Aug 15;470(1-2):141-50. doi: 10.1016/j.ijpharm.2014.04.060. Epub 2014 May 9.
9
ARTcrystal process for industrial nanocrystal production--optimization of the ART MICCRA pre-milling step.ARTcrystal 工艺用于工业纳米晶体生产——ART MICCRA 预粉碎步骤的优化。
Int J Pharm. 2014 Apr 25;465(1-2):388-95. doi: 10.1016/j.ijpharm.2014.02.026. Epub 2014 Feb 17.
10
PVP and surfactant combined carrier as an effective absorption enhancer of poorly soluble astilbin in vitro and in vivo.PVP 和表面活性剂复合载体作为一种有效的吸收增强剂,可提高难溶性梓醇的体外和体内吸收。
Drug Dev Ind Pharm. 2014 Feb;40(2):237-43. doi: 10.3109/03639045.2012.756008. Epub 2013 Jan 28.